Plus Therapeutics
PSTV
PSTV was delisted on the 31st of July, 2026.
11 hedge funds and large institutions have $2.48M invested in Plus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
21% less funds holding
Funds holding: 14 → 11 (-3)
40% less capital invested
Capital invested by funds: $4.11M → $2.48M (-$1.64M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$259K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.58K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$2.29K |
| 4 |
State Street
Boston,
Massachusetts
|
+$763 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$232K |
| 2 |
VF
Virtu Financial
New York
|
-$195K |
| 3 |
Two Sigma Investments
New York
|
-$187K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$111K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$86.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $1.36M | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $493K | +$259K | +340 | +97% |
|
3
BlackRock
New York
| $245K | -$64.1K | -84 | -20% |
|
|
4
Two Sigma Advisers
New York
| $117K | -$232K | -304 | -65% |
|
|
5
State Street
Boston,
Massachusetts
| $66K | +$763 | +1 | +1% |
|
6
Northern Trust
Chicago,
Illinois
| $61K | -$16.8K | -22 | -20% |
|
|
7
Dimensional Fund Advisors
Austin,
Texas
| $49K | -$86.9K | -114 | -63% |
|
8
Creative Planning
Overland Park,
Kansas
| $35K | – | – | – |
|
|
9
Two Sigma Investments
New York
| $31K | -$187K | -245 | -85% |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| $17K | +$2.29K | +3 | +14% |
|
|
11
Bank of America
Charlotte,
North Carolina
| $4K | +$4.58K | +6 | New |
|
|
FP
12
Financial Perspectives
Minneapolis,
Minnesota
| $2 | – | – | – |
|
|
VF
13
Virtu Financial
New York
| – | -$195K | -203 | Closed |
|
|
14
Citadel Advisors
Miami,
Florida
| – | -$111K | -116 | Closed |
|
15
Renaissance Technologies
New York
| – | -$45K | -47 | Closed |
|
|
SFI
16
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$33K | -35 | Closed |
|
PSTV Hedge Fund Activity: Q3 2021 in Review
11 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2021, worth a combined $2.48M — down 40% from $4.11M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PSTV and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 3 added.
The largest buyer was Geode Capital Management, adding an estimated $259K. The largest seller was Two Sigma Advisers, cutting an estimated $232K.
- 11 institutional investors held Plus Therapeutics (PSTV) as of Q3 2021, down from 14 in Q2 2021.
- Funds reported $2.48M of Plus Therapeutics stock for Q3 2021, down 40% quarter-over-quarter.
- 1 fund opened new Plus Therapeutics positions in Q3 2021 and 4 closed out, a net change of -3 holders.
- The largest Plus Therapeutics buyer in Q3 2021 was Geode Capital Management, an estimated $259K added.
- The largest Plus Therapeutics seller in Q3 2021 was Two Sigma Advisers, an estimated $232K sold.
Based on aggregated 13F filings for Q3 2021.